Uncategorized
Trefoil Therapeutics working with NIH to develop compound for Fuchs’ dystrophy
Trefoil Therapeutics is working with the National Institutes of Health to complete investigational new drug activities for a compound to treat Fuchs’ endothelial corneal dystrophy, according to a news release.Trefoil is collaborating with the NIH’s National Center for Advancing Translational Sciences to accelerate the development of the company’s lead compound, TTHX1114.